Drugs / DELANZOMIB
DELANZOMIB
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00572637 | Nov 2007 → Mar 2010 | cancer, non-Hodgkin lymphoma | Ethical Oncology Science | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01348919 | Aug 2011 → Mar 2013 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01023880 | Jan 2010 → Nov 2012 | plasma cell myeloma | Cephalon | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DELANZOMIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL270515 ↗ |
| Known as | CEP 18770 | “This is an open-label, multicenter, dose-escalating study to determine the MTD and dose limiting toxicities (DLTs) of CEP 18770, a novel proteasome inhibitor.” NCT00572637 ↗ |
| Known as | CIP 18770 | ChEMBL registry synonym — accepted as the source's own label CHEMBL270515 ↗ |
| Known as | CT 47098 | ChEMBL registry synonym — accepted as the source's own label CHEMBL270515 ↗ |
| Known as | NPH 007098 | ChEMBL registry synonym — accepted as the source's own label CHEMBL270515 ↗ |
| Action | Inhibit | “CEP 18770, a novel proteasome inhibitor” NCT00572637 ↗ |
| Modality | Small molecule | “Delanzomib (CEP-18770), a reversible P2 threonine boronic acid proteasome (β5/β1 subunits) inhibitor” PMID 28140719 ↗ Jan 2017 |
| Route | Intravenous | “Patients will be treated intravenously with CEP 18770 on days 1, 4, 8, and 11 of a 21-day cycle period.” NCT00572637 ↗ |